Clinical Trial Update: Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluating the cardiovascular safety parameters of sorafenib (BAY 43-9006) in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED